about
Hybrid Imaging for Patient-Specific Dosimetry in Radionuclide TherapyDevelopment and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy.Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.Dynamic (99m)Tc-MAG3 renography: images for quality control obtained by combining pharmacokinetic modelling, an anthropomorphic computer phantom and Monte Carlo simulated scintillation camera imaging.Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in (177)Lu-DOTATATE peptide receptor radionuclide therapy.3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations.Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.On the biologically effective dose (BED)-using convolution for calculating the effects of repair: II. Numerical considerations.Testis dosimetry in individual patients by combining a small-scale dosimetry model and pharmacokinetic modeling-application of (111)In-Ibritumomab Tiuxetan (Zevalin(®)).Evaluation of quantitative (90)Y SPECT based on experimental phantom studies.Gamma camera imaging for studying intestinal absorption and whole-body distribution of selenomethionine.Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey.The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.High resolution pinhole SPECT for tumor imaging.Patient-specific whole-body attenuation correction maps from a CT system for conjugate-view-based activity quantification: method development and evaluation.Biologically effective dose in fractionated molecular radiotherapy--application to treatment of neuroblastoma with (131)I-mIBG.Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131 I-NaI treatments of differentiated thyroid cancer.On the biologically effective dose (BED)-using convolution for calculating the effects of repair: I. Analytical considerations.The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy.A new method to obtain transmission images for planar whole-body activity quantification.MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.Uncertainty propagation for SPECT/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy.Registration of serial SPECT/CT images for three-dimensional dosimetry in radionuclide therapy.Parametric images of antibody pharmacokinetics based on serial quantitative whole-body imaging and blood sampling.The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study.90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy.Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools.Consequences of inadvertent radioiodine treatment of Graves’ disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing?Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer
P50
Q26768478-23D18EF0-D14A-4891-9A48-8E7848F4FF1CQ33412527-5322FCC2-0B33-4B0F-B6C5-968330FC1D23Q38219225-F737BDE4-9862-4C41-B23C-CABC3D85306CQ38753821-E0D53F99-6C35-432D-9239-3F86A88AAA2BQ38884776-EB73691D-7F36-4E6B-9B07-9363C9FEC636Q39904007-A8F1D09B-EEF4-4452-938E-68DAB5D90718Q40106530-6C3C0E73-529B-4F28-BD3D-8542D8215185Q40300078-E7164B43-DCB5-460D-9A01-0937B1A484F4Q40597097-965FDCB7-5651-4B6F-BDAF-C787208DFCC4Q40777229-7F7171CA-7B5A-4AE3-90E7-A5680CDBD7F7Q40913291-0CB95B66-0902-4FD0-B3B2-AFB970375EFDQ43297419-AC0F4ED2-4A62-490A-B2B8-EF596C991479Q43892406-05025D3A-5B3C-4B6A-8062-4123946C05A4Q45901562-37C6B1CA-A36E-45DC-9CD4-E26229F77003Q46287958-AB18C190-ED98-46A6-97CC-F56FE498EEFCQ46493849-CFADEE78-0FBC-4081-8357-D3A98BFEC5ACQ47289157-59A8B84A-2318-4110-A1EB-6C0F31628997Q48109617-5811D9C1-08CA-40AB-A842-5DDEC18DD8A3Q48376478-759EF517-8FD8-40C2-84E8-3A979EED112DQ48556587-DA22ED6E-BEFB-4225-A917-4A090177D20AQ50697960-DB666EA4-0785-4D8B-9BDE-A9AA9A4A5E43Q50943856-EE27CD07-DB1C-4FC7-9F21-2B48AC47130CQ51259474-B10B73FD-3013-46B0-9801-994916867501Q51526520-C8843F45-A40D-4561-8691-B7ECCF9FF6D0Q51526528-98716378-BB54-408F-8D93-667BF1C5F12AQ51684322-EDC233EE-08A6-49AB-8F76-AF141334CEE5Q51689323-EAB97CBD-F055-42BF-80A6-B82B77129498Q51788338-FEE3053C-0946-4929-B537-3FC2E91789FDQ53025580-CE1ECE66-FEB6-4B6A-8000-4909DFE322D1Q53213092-8A6379AE-76C2-41DD-8C34-CE7A1270C187Q53260892-A21A3DAE-AF13-4E19-973C-F9DA0AE7A7B7Q54193722-B9090CEE-8BCA-43AA-AE5C-6FC311E24876Q59624221-C55C4C53-14F7-4C9C-8F52-B3D20CF4F8FEQ95801572-73CFC2FD-F8CC-475C-9E9C-43FB13480470
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Katarina Sjögreen Gleisner
@ast
Katarina Sjögreen Gleisner
@en
Katarina Sjögreen Gleisner
@es
Katarina Sjögreen Gleisner
@nl
Katarina Sjögreen Gleisner
@sl
type
label
Katarina Sjögreen Gleisner
@ast
Katarina Sjögreen Gleisner
@en
Katarina Sjögreen Gleisner
@es
Katarina Sjögreen Gleisner
@nl
Katarina Sjögreen Gleisner
@sl
prefLabel
Katarina Sjögreen Gleisner
@ast
Katarina Sjögreen Gleisner
@en
Katarina Sjögreen Gleisner
@es
Katarina Sjögreen Gleisner
@nl
Katarina Sjögreen Gleisner
@sl
P106
P21
P31
P496
0000-0001-5664-8760